ISRCTN77853517已完成未知
Ocular discomfort following use of artificial tears in patients under treatment of intravitreal injections of anti-vascular endothelial growth factor agents
Oftalmología Vistahermosa S0 个研究点目标入组 34 人开始时间: 2021年2月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 34
研究概览
简要总结
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36474999/ (added 08/12/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 06/04/2021:
- •1. Patients with anti-vascular endothelial growth treatment with Lucentis 10mg/ml (ranibizumab, Novartis) for age-related macular degeneration
- •2. Patients must have already received a minimum of three injections of this treatment
- •3. Age between 51 and 90 years
- •Previous inclusion criteria:
- •1. Patients with anti-vascular endothelial growth treatment with Lucentis 10mg/ml (ranibizumab, Novartis) for age-related macular degeneration
- •2. Patients must have already received a minimum of three injections of this treatment
- •3. Age between 50 and 90 years
排除标准
- •1. Glaucoma
- •2. Dry eye
- •3. Previous refractive surgery or recent cataract surgery (less than 6 months)
研究者
相似试验
已完成
2 期
Efficacy of a New Nanoemulsion Artificial Tear Targeting Dry Eye DiseaseDry Eye SyndromesNCT06188260The Hong Kong Polytechnic University31
已完成
4 期
Efficacy and Acceptability of Two Lubricant Eye DropsDry Eye SyndromesNCT00756678Allergan51
已完成
4 期
Non-Pharmaceutical Treatment of Seasonal Allergic ConjunctivitisHypersensitivityNCT01569191Aston University18
已完成
不适用
Safety and Efficacy of an Artificial Tear for the Treatment of Dry EyeDry Eye SyndromeNCT00514852Allergan316
已完成
不适用
Systane Ultra Versus Maxidex Versus SalineDry Eye DiseaseNCT01775540Icahn School of Medicine at Mount Sinai36